ArticleAlimentary pharmacology & therapeutics2026
Antiviral Therapy and Post-Resection Outcomes in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antiviral Therapy and Post-Resection Outcomes in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsThe comparative outcomes of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection remain unclear. This study aimed to evaluate the survival benefits of these antiviral regimens in a large real-world cohort.
methodsWe analysed 902 patients with BCLC stage 0 or A HBV-related HCC who underwent curative resection between September 2001 and August 2025. Patients received ETV (n = 474), TDF (n = 363), or TAF (n = 65) as first-line therapy within 3 months post-resection. Inverse probability of treatment weighting (IPTW) was implemented to balance baseline covariates. The primary and secondary endpoints were overall survival (OS) and recurrence-free survival (RFS).
resultsThe IPTW-adjusted 5-year OS rates for ETV, TDF, and TAF were 90.7%, 95.2%, and 97.1%, respectively (global p = 0.079). The 5-year RFS rates were comparable for ETV, TDF, and TAF (57.4% vs. 61.0% vs. 69.4%; global p = 0.533). In multivariable Cox regression analysis, however, TDF was independently associated with a significantly lower risk of death compared with ETV (aHR 0.48; 95% CI, 0.26-0.89; p = 0.021). TAF showed higher survival rates compared to ETV, although the difference did not reach statistical significance (aHR 0.34; 95% CI, 0.04-2.55; p = 0.292).
conclusionThe choice of antiviral regimen was not associated with RFS after curative resection for HBV-related HCC, whereas TDF was independently associated with improved OS compared with ETV. Further large-scale studies are warranted to validate the long-term prognostic impact of TAF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.